R&D / Assay Development

The Sirona Dx Research and Development team is technology agnostic and works closely with our pharma clients to select the most appropriate methods and platforms. Our team applies cutting-edge technologies & a wide range of platforms in the development of high-complexity genomic assays.

Our Cancer Hotspot Panel allows the interrogation of hotspot regions of 50 oncogenes and tumor suppressor genes, with wide coverage of the KRAS, BRAF, and EGFR genes. This panel requires only 10 ng of DNA facilitating the sequencing of challenging samples like FFPE tissue.

RD Assay Development

JAK3 ABL1 EZH2 PTEN
IDH2 AKT1 FBXW7 PTPN11
KDR ALK FGFR1 RB1
KIT APC FGFR2 RET
KRAS ATM FGFR3 SMAD4
MET BRAF FLT3 SMARCB1
MLH1 CDH1 GNA11 SMO
MPL CDKN2A GNAS SRC
NOTCH1 CSF1R GNAQ STK11
NPM1 CTNNB1 HNF1A TP53
NRAS EGFR HRAS VHL
PDGFRA ERBB2 IDH1  
PIK3CA ERBB4 JAK2  

We combine demanding clinical validation with the flexibility to customize assay parameters and reporting formats based on the sponsor's clinical study requirements. We use a variety of molecular approaches tailored to the client's needs, including Next Generation Sequencing, exome sequencing, bioinformatics, targeted resequencing, RT-PCR for gene expression, SNP analysis, and Capillary Electrophoresis. Our laboratory offers multiple platforms for the detection of mutations, copy number variations, and expression levels. Our extensive clinical validation guarantees robust performance and accuracy.